Charlotte B Wagner

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen, Surbhi Sidana, Lauren C. Peres et al. · Journal of Clinical Oncology · 2023 · 279 citations · Full text

Medicine, Immunology, Oncology +15

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana, Krina K. Patel, Lauren C. Peres et al. · Blood · 2024 · 124 citations · Full text

Medicine, Hematology, Oncology +14

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi et al. · Blood Cancer Journal · 2023 · 111 citations · Full text

Medicine, Hematology, Oncology +17

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima et al. · Journal of Clinical Oncology · 2025 · 35 citations · Full text

Medicine, Immunology, Oncology +16

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience

Hamza Hashmi, Doris K. Hansen, Lauren C. Peres et al. · Haematologica · 2023 · 34 citations · Full text

Medicine, Hematology, Immunology +16